Clinical trial · Interventional
Treosulfan-based Conditioning for Transplantation in AML/MDS
Phase II Trial of Fludarabine Combined With Intravenous Treosulfan and Allogeneic Hematopoietic Stem-cell Transplantation in Patients With Chemo-refractory or Previously Untreated Acute Myeloid Leukemia and Myelodysplastic Syndrome.
NCT00491634CI-TRIAL-00019999completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The study hypotheses is that the introduction of dose escalated treosulfan, in substitution to busulfan, will reduce toxicity after allogeneic transplantation while improving myeloablation and and disease control in patients with AML and MDS not eligible for standard transplantation.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Myeloid Leukemia | Acute Myeloid Leukemia | CURATED_BROADER | 0.80 |
| Myelodysplastic Syndrome | Myelodysplastic Syndrome | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| treosulfan | Drug | Treosulfan | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- 1
- description
- treosulfan
- interventionNames
- Drug: treosulfan
Primary outcomes (1)
- measure
- disease-free survival
- timeFrame
- 2 years after transplantation
Secondary outcomes (1)
- measure
- treatment-related mortality, GVHD, relapse, overall survival
- timeFrame
- 2 year after transplantation
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 68 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age less than physiologic 68 years. 2. Patients with AML and MDS not eligible for standard TBI- or Busulfan-based myeloablative conditioning due to age, concurrent medical condition, or extensive prior therapy (e.g. age \> 55 years for HLA-matched sibling transplants or \> 50 for matched unrelated donor transplants, prior / concomitant pulmonary, liver, or other organ complications). 3. This study will only include patients with chemo-refractory disease or previously untreated active disease. A. acute myeloid leukemias (AML) according to WHO classification (\> 20% myeloblasts in peripheral blood or bone marrow at diagnosis) in induction failure, PR, untreated or chemo-refractory relapse. Patients must have \> 10% marrow blasts at the time of transplantation. B. myelodysplastic syndromes (MDS) according to WHO classification (\< 20% myeloblasts in peripheral blood and bone marrow at diagnosis), indicated for allogeneic transplantation: \- refractory anaemia with excess blasts (RAEB-1 and RAEB-2) with no prior therapy 4. Patients must have an HLA matched related or unrelated donor willing to donate either peripheral blood stem cells or bone marrow. Matching is based on high-resolution class I (HLA-A, -B, -C) and class II (HLA-DRB1, -DQB1) typing. The goal is to transplant \> 3 x 106 CD34+ cells per kg body weight of the recipient - Exclusion Criteria: 1. Bilirubin \> 3.0 mg/dl, transaminases \> 3 times upper normal limit 2. Creatinine \> 2.0 mg/dl 3. ECOG-Performance status \> 2 4. Uncontrolled infection 5. Pregnancy or lactation 6. Abnormal lung diffusion capacity (DLCO \< 40% predicted) 7. Severe cardiovascular disease 8. CNS disease involvement 9. Pleural effusion or ascites \> 1 liter 10. Known hypersensitivity to fludarabine or treosulfan 11. Psychiatric conditions/disease that impair the ability to give informed consent or to adequately co-operate -
References
Publications (1)
- BACKGROUNDKroger N, Shimoni A, Zabelina T, Schieder H, Panse J, Ayuk F, Wolschke C, Renges H, Dahlke J, Atanackovic D, Nagler A, Zander A. Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS). Bone Marrow Transplant. 2006 Feb;37(4):339-44. doi: 10.1038/sj.bmt.1705259. PMID 16415898